Teva Withholds NDA for MS Drug Laquinimod Following FDA Talks

After recent discussions with the FDA, Teva Pharmaceuticals has decided not to file an NDA for relapsing remitting multiple sclerosis (RRMS) treatment laquinimod but plans to keep developing and studying the drug. Teva declined to detail its October talks with the FDA on laquinimod, saying only that further studies of the drug as a monotherapy and an add-on therapy in RRMS patients are planned.
Drug Industry Daily